ET
Elixirgen Therapeutics
- Business Model
- B2B
- Total Funding
- $4.0M
- Last Round
- $4.0M Series AJul 2018
- Rounds
- 1
About
Development of revolutionary cures for rare diseases using ZSCAN4 cell therapy
Summary
Elixirgen Therapeutics is a Biotech company. It has raised $4.0M in total across 1 round, most recently a $4.0M Series A round in Jul 2018. Investors include University of Tokyo Edge Capital.
Funding History
$4.0M
Jul 2018
Investors
Similar Companies
Tiantan Biological / China Biologic (泰邦生物集团)
China's leading blood products manufacturer
Beijing, China1001–5000Biotech, Healthcare
Growth Equity·$5.1B·Aug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired
Global contract research organization providing comprehensive drug development and laboratory ser...
Wilmington, United States10001+Biotech, Healthcare
Private Equity·$3.9B·Jan 2019
IVI-RMA
Global fertility clinics platform
Valencia, Spain5001–10000Biotech, Healthcare
Private Equity·$3.3B·Apr 2022
Altos Labs
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
San Francisco, United States501–1000Life Sciences, Biotech
Series A·$3.0B·Jan 2022
inVentiv HealthAcquired
Biopharmaceutical services company
Burlington, United States5001–10000Biotech, Healthcare
Private Equity·$3.0B·May 2017
Warner ChilcottAcquired
Specialty pharmaceutical company
Rockaway, United States1001–5000Biotech, Healthcare
Private Equity·$3.0B·Jan 2004
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/elixirgen-therapeutics"><img src="https://indexed.vc/api/badge/company/elixirgen-therapeutics" alt="Elixirgen Therapeutics on Indexed.vc" width="260" height="76" /></a>